"Liberation treatment" for chronic cerebrospinal venous insufficiency in multiple sclerosis: the truth will set you free

Georgios Tsivgoulis, Simon Faissner, Konstantinos Voumvourakis, Aristeidis H. Katsanos, Nikos Triantafylou, Nikolaos Grigoriadis, Ralf Gold & Christos Krogias

Keywords: Chronic cerebro-spinal venous insufficiency, iron, "Liberation" treatment, multiple sclerosis, transcranial sonography, ultrasound, venous angioplasty.

Correspondence: Georgios Tsivgoulis, Second Department of Neurology, University of Athens, School of Medicine, Iaras 39, Gerakas Attikis, Athens 15344, Greece. Tel: +30 693 717 8635; Fax: +30 210 583 2471; E-mail: tsivgoulisgiorg@yahoo.gr

Funding Information: No funding information provided.

Received: 4 September 2014; Revised: 19 October 2014; Accepted: 23 October 2014

Brain and Behavior 2015; 5(1), e00297, doi: 10.1002/brb3.297

Abstract

Background: Chronic cerebrospinal venous insufficiency (CCSVI) has recently been introduced as a chronic state of impaired cerebral or cervical venous drainage that may be causally implicated in multiple sclerosis (MS) pathogenesis. Moreover, percutaneous transluminal angioplasty of extracranial veins termed “Liberation treatment” has been proposed (based on nonrandomized data) as an alternative therapy for MS. Methods: A comprehensive literature search was conducted to identify available published, peer-reviewed, clinical studies evaluating (1) the association of CCSVI with MS, (2) the reproducibility of proposed ultrasound criteria for CCSVI detection (3) the safety and efficacy of “Liberation treatment” in open-label and randomized-controlled trial (RCT) settings. Results: There is substantial heterogeneity between ultrasound case–control studies investigating the association of CCSVI and MS. The majority of independent investigators failed to reproduce the initially reported high prevalence rates of CCSVI in MS. The prevalence of extracranial venous stenoses evaluated by other neuroimaging modalities (contrast or MR venography) is similarly low in MS patients and healthy individuals. One small RCT failed to document any benefit in MS patients with CCSVI receiving “Liberation treatment”, while an exacerbation of disease activity was observed. “Liberation treatment” has been complicated by serious adverse events (SAEs) in open-label studies (e.g., stroke, internal jugular vein thrombosis, stent migration, hydrocephalus). Conclusion: CCSVI appears to be a poorly reproducible and clinically irrelevant sonographic construct. “Liberation treatment” has no proven efficacy, may exacerbate underlying disease activity and has been complicated with SAEs. “Liberation treatment” should stop being offered to MS patients even in the settings of RCTs.

Introduction

Multiple sclerosis (MS) is a chronic, primary inflammatory disease of the central nervous system (Gold et al. 2006). In 2009, a new concept for the pathogenesis of MS based on the idea of an impaired cerebrospinal venous drainage was postulated, differing from the established concept of the multifactorial pathogenesis of MS (Zamboni et al. 2009a). This hypothesis was based on specifically developed ultrasound features which were stated to detect cervical or cerebral abnormalities of venous drainage leading to increased intracranial venous pressure, subsequently followed by blood–brain barrier breakdown causing iron deposition in brain parenchyma initiating the development of MS (Zamboni 2006). Moreover, percutaneous transluminal angioplasty of extracranial veins...
(termed “Liberation treatment”) has been proposed (based on nonrandomized data) as an alternative therapy for MS by the same group of investigators introducing CCSVI hypothesis (Zamboni et al. 2009c). Despite the lack of higher class evidence “Liberation treatment” has gained a considerable amount of attention and emotional involvement by MS patients worldwide (Chafe et al. 2011) and has started to be offered as a potential therapeutic option in MS patients in nonrandomized and uncontrolled studies (Hubbard et al. 2012; Mandato et al. 2012; Ghezzi et al. 2013b).

However, numerous independent investigators failed to detect any association between CCSVI neurosonology criteria and MS in numerous case-control studies, while “Liberation treatment” has been complicated with serious adverse events (SAEs) leading to substantial criticism of “venous hypothesis” of MS pathogenesis (Barkhof and Wattjes 2013; Valdueza et al. 2013).

Methods
In view of the former considerations, we conducted a comprehensive literature search to identify available published, peer-reviewed, clinical studies evaluating (1) the association of CCSVI with MS using different ultrasound modalities, (2) the reproducibility of proposed ultrasound criteria for CCSVI detection, (3) the safety and efficacy of “Liberation treatment” in open-label and randomized-controlled trial (RCT) settings.

Our literature search through MEDLINE was based on the combination of terms “Chronic cerebro-spinal venous insufficiency”, “multiple sclerosis”, “transcranial sonography”, “iron”, “ultrasound”, “Liberation treatment,” and “venous angioplasty”. Last literature search was conducted on 14 August, 2014. Reference lists of all articles that met the criteria and of relevant review articles were examined to identify studies that may have been missed by the database search. Titles, abstracts and, whenever appropriate, full texts of all identified studies were screened independently by two reviewers in English (GT, CK) and two reviewers in German (SM, CK) journals. Potential disagreements were resolved by consensus of all contributing authors. Duplicate publications and publications in other than the English or German language were excluded from further evaluation.

Results

The venous hypothesis of the pathogenesis of MS
The “venous hypothesis” postulates that disturbances of the venous drain from the cervical and/or spinal venous system leads to a congestion and increase in the intracranial venous pressure (Singh and Zamboni 2009). Given his experience in vascular surgery, Dr Zamboni who introduced the “CCSVI hypothesis” saw pathophysiological parallels between a chronic state of cervical or cerebral venous insufficiency and MS (Zamboni 2006). Similar to the chronic venous insufficiency (CVI) in the leg veins, he postulated that cerebral venous stasis may induce endothelial damage leading to blood–brain barrier disruption, which in turn may result in extravasation of erythrocytes (Zamboni 2006). He also hypothesized that disintegrating erythrocytes may be dismounted by macrophages which may cause a local deposition of iron (Ackermann et al. 1988). The focal increased amount of iron may in turn induce a chronic inflammatory reaction with an upregulation of the migration of leukocytes in the subcutaneous matrix via expression of adhesion molecules (ICAM, VCAM) and of selectins (Colleridge-Smith et al. 1988). He underlined that macrophages and T-lymphocytes will play a predominant role in this process, since macrophages have been shown to phagocyte the accumulated iron in subcutaneous tissue and store it intracellularly (Wilkinson et al. 1993; Takase et al. 2004). Moreover, the CCSVI hypothesis underscores that extracellular depositions and iron-loaded macrophages are not only the histopathological feature of CVI but can also be found in MS plaques (Adams et al. 1989) and have been shown to stimulate the immune system (Weilbach et al. 2004). The fact that MS-plaques are located in the perivenous region led to the hypothesis that the pathophysiology of MS may be mediated through a chronic inflammatory reaction whose cause lays in the impaired venous outflow (as well as in CVI).

This hypothesis acquired a high resonance in some patient groups as well as in the media, as it was presented as a comprehensible, potentially curable cause of MS which was easy to understand (Pullman et al. 2013). Moreover, patient organisations and advocacy groups, scientific societies, and health-care authorities started funding CCSVI at an International level (Canada, Italy, United States) under pressure from the media and the blogosphere (Pullman et al. 2013).

External validation of ultrasound criteria for CCSVI detection
Zamboni et al. reported in their pivotal study that neurosonology had 100% accuracy parameters (sensitivity, specificity, positive predictive value, negative predictive value) to discriminate MS patients from Healthy Controls (HC) using a set of ultrasound criteria developed to detect impaired cervical or venous drainage (Zamboni et al. 2009b). Consequently, they introduced evidence of
two positive out of five proposed ultrasound criteria as necessary condition for CCSVI diagnosis (Table 1, Fig. 1) (Zamboni et al. 2009a). Moreover, they recommended a detailed neurosonology protocol for CCSVI screening (Nicolaides et al. 2011). However, it should be noted that blinding of sonographers was suboptimal in the majority of studies of Zamboni’s group.

A series of studies conducted by independent investigators failed to reproduce the findings reported by Zamboni and coworkers in their pivotal studies. In a first ad-hoc investigation of a small unselected group of MS patients in Bochum, the prevalence of CCSVI was similar in MS patients (20%) and HC (10%) (Krogias et al. 2010). In a larger investigation conducted in Berlin, CCSVI criteria were not met in a single individual out of 56 investigated patients (Doepp et al. 2010). In a North-American study using sonographers trained by Zamboni, a higher prevalence of CCSVI was documented in MS patients (63%) than in HC (26%) (Zivadinov et al. 2011). Moreover, a post hoc analysis indicated that CCSVI was independently associated with a more progressive MS course. The association of CCSVI and MS was also reproduced by a Jordanian (Al-Omari and Roussan 2010) and a Polish (Zaniewski et al. 2013) group of investigators that were also offering “Liberation treatment” in their MS patients.

In contrast to the previous observations, an Italian study, investigating only MS patients with clinically isolated syndrome, reported a normal ultrasound investigation in 84% of study population (Baracchini et al. 2011). Moreover, CCSVI could not be detected in additional series of MS patients investigated in Greece (Tsivgoulis et al. 2011) and Germany (Frankfurt/Giessen) (Mayer et al. 2011). In addition, the largest to date, methodologically robust (using both local and central blinded readers) ultrasound case–control study involving 1874 subjects from 35 Italian centers reported a similar (very low) prevalence of CCSVI in MS (3%) and HC (2%) (Comi et al. 2013). Interestingly, the poor interrater and intrarater agreement in CCSVI ultrasound criteria reported both by Italian (Comi et al. 2013) and Greek (Tsivgoulis et al. 2011) investigators underscore the lack of reproducibility of the proposed neurosonology protocol (Table 2). More specifically, the positive agreement between central and local readers in the Italian study was disappointingly low (18%) (Comi et al. 2013). Finally, in an assessor-blinded, case–control, multicentre Canadian study using doppler ultrasound equipment identical to that used in the pivotal study by Zamboni et al. (2009a) and experienced sonographers trained in the center of Zamboni in Ferrara, the prevalence of CCSVI was similar in MS (44%) and HC (45%) (Traboulsee et al. 2014).

In view of the discrepant results between different investigators, recent meta-analyses (Laupacis et al. 2011; Krogias et al. 2013; Zwischenberger et al. 2013; Tsivgoulis et al. 2014) have suggested an independent association between

Table 1. Proposed ultrasound criteria for CCSVI diagnosis (at least two criteria present).

| Criterion | Description |
|-----------|-------------|
| I         | Reflux constantly present in internal jugular veins (IJV) or vertebral veins (VV) with the head at 0° (supine position) and +90° (upright position) assessed as flow reversal from its physiologic direction for a duration of >0.88 sec during a short period of apnea following a normal exhalation reflux constantly present in Internal Jugular Vein (IJV) and or Vertebral Vein (VV) |
| II        | Reflux in deep cerebral veins (DCVs) assessed as the presence of flow reversal for a duration of >0.50 sec during normal breathing in at least one of the following three DCVs: basal vein of Rosenthal (BVR), great vein of Galen (GVG), and internal cerebral vein (ICV) |
| III       | High-resolution B-mode evidence of proximal IJV stenosis (defined as local reduction in cross-sectional area > 50% or cross-sectional area <0.3 cm2 at the supine position) |
| IV        | Flow not Doppler detectable in the IVs and/or VVs with the head positioned at 0° (Fig. 1) and +90° |
| V         | Reverted postural control of the main cerebral venous outflow assessed as negative difference of the cross-sectional area (CSA) in the IJVs measured in the supine position subtracted from the cross-sectional area in the IJVs measured in the upright position |

Figure 1. Flow not-Doppler detectable in the Internal Jugular Vein (Criterion IV) in horizontal color-flow image before (A) and after (B) spectral interrogation.
Table 2. Inter- and intrarater agreement of ultrasound criteria for CCSVI diagnosis.

| Study             | Number of patients | Zamboni’s Group | Findings |
|-------------------|--------------------|-----------------|----------|
| Menegetti et al. 2010 | 36 (12 MS, 12 HC, 12 OND) | Yes             | 1 Interrater reliability between trained and not trained sonographers in Zamboni’s center: $\kappa = 0.47$
|                   |                    |                 | 2 Interrater reliability between trained sonographers: $\kappa = 0.80$
|                   |                    |                 | 3 Intra-rater reliability in trained sonographers: $\kappa = 0.93$
| Tsivgoulis et al. 2011 | 15 (8 MS, 7HC)     | No              | 1 Interrater reliability regarding criterion I, III & IV: $\kappa = 0.82$–1.00
|                   |                    |                 | 2 Interrater reliability regarding Criterion II & IV: $\kappa = 0.14$–0.48
| Zivadinov et al. 2011 | 36 (11 MS, 14 HC, 3 OND) | Yes             | 1 Interrater reliability: not available
|                   |                    |                 | 2 Intra-rater reliability: $\kappa = 0.75$
| Corni et al. 2013 | 1767 (1165 MS, 376 HC, 226 OND) | No              | 1 Interrater reliability between local and central readers: $\kappa = 0.13$
|                   |                    |                 | Negative agreement: 92% (90–93%)
|                   |                    |                 | Positive agreement: 18% (13–22%)

MS, Multiple sclerosis; HC, Healthy Controls; OND, Other Neurological Disorders.

Table 3. Summary of multimodal neuroimaging studies investigating the CCSVI hypothesis in multiple sclerosis.

| Study             | Imaging modalities | Main findings |
|-------------------|--------------------|---------------|
| Baracchini et al. 2011 | DS, CV          | • CV did not confirm venous outflow abnormalities in seven CCSVI (+) patients according to DS criteria |
| Blinkenberg et al. 2012 | DS, MRI, PC-MR   | • DS and MRI documented no evidence supporting the CCSVI hypothesis |
| Brod et al. 2013 | DS, MRV, TLV     | • The three imaging approaches provided generally consistent data not supporting the CCSVI hypothesis
|                   |                    | • No evidence for altered venous outflow in MS patients |
| Costello et al. 2014 | DS, MRV         | • DS and MRV documented no evidence supporting the CCSVI hypothesis |
| Dolic et al. 2011 | DS, MRV         | • A multimodal noninvasive approach increases the specificity for CCSVI diagnosis in MS patients |
| Dolic et al. 2012 | DS, MRV         | • DS is more sensitive than MRV in detecting intraluminal structural and functional venous abnormalities in patients with MS compared with controls |
| Hojnacki et al. 2010 | DS, MRV, CV     | • The use of MRV for diagnosis of CCSVI in MS patients has limited value, and the findings should be interpreted with caution and confirmed by other imaging techniques, such as DS and CV |
| Rodger et al. 2013 | DS, MRV         | • DS and MRI documented no evidence supporting the CCSVI hypothesis |
| Simka et al. 2012 | DS, CV          | • DS criteria for the detection of obstructive venous abnormalities are of limited diagnostic value and diagnosis should be given using CV |
| Traboulsee et al. 2014 | DS, CV         | • Although CCSVI occurs rarely in MS patients and controls, extracranial venous narrowing >50% is frequent in both groups
|                   |                    | • The prevalence of CCSVI on CV is low (<5%) in MS patients and healthy controls |
|                   |                    | • The DS criteria are neither sensitive nor specific for narrowing on CV |
| Zivadinov et al. 2011 | DS, MRV, CV    | • DS showed high specificity and PPV, as well as strong agreement with CV findings at baseline
|                   |                    | • In contrast, conventional MRV had limited value for the detection of venous abnormalities both cross-sectionally and longitudinally |
| Zivadinov et al. 2012 | DS, MRI         | • CCSVI is not associated with more severe lesion burden or brain atrophy in MS patients or controls |
| Zivadinov et al. 2013 | DS, MRV, CV     | • DS screening was found to be a reliable approach for identifying patients eligible for further multimodal invasive imaging testing |

DS, doppler ultrasound; PC-MR, phase-contrast magnetic resonance imaging; MRV, magnetic resonance venography; CV, catheter venography; MRI, magnetic resonance imaging; CP, cervical plethysmography; MS, multiple sclerosis; CCSVI, chronic cerebrospinal venous insufficiency; TVL, transluminal venography; IJV, internal jugular vein; PPV, positive predictive value.
intracranial or extracranial veins with significant stenosis in patients with MS. This finding is in contrast to the CCSVI hypothesis, which suggests that venous abnormalities, particularly in the jugular veins, are a causative factor in MS. The authors of this study analyzed and summarized existing literature on ultrasound assessments of extracranial venous drainage in MS, concluding that there is limited evidence supporting the CCSVI hypothesis and emphasizing the need for further research to clarify its implications for MS treatment and management.

**Table 4. Methodological shortcomings of proposed neurosonology protocol for CCSVI diagnosis (Baracchini et al. 2011; Tsvigoulis et al. 2011; Valdueza et al. 2013).**

| Criterion | Methodological shortcoming |
|-----------|----------------------------|
| (I): Reflux in cervical veins | 1. The threshold of 0.88 sec for diagnosing "reflux" in cervical veins has been validated only for internal jugular valve (IJV) valve insufficiency [no validation for Vertebral Veins (VV)] |
| | 2. Nonpathologic oscillating signal with positive and negative flows can be observed in IJV especially in the oldest old [pulsation of internal carotid artery (ICA)] leading to false-positive diagnosis of extracranial venous reflux |
| | 3. Two different time values have been used to define extracranial (0.88 sec) and intracranial (0.55 sec) reflux |
| (II): Reflux in deep cerebral veins | 1. Introduction of a novel acoustic window by Zamboni termed "supracondylar" (substituting classic transtemporal window) |
| | 2. Evaluation of intracranial venous reflux using only Color-Coded Mode analysis (mandatory Doppler spectrum analysis) leading to false-positive diagnosis of intracranial venous reflux |
| | 3. The detection rate of reflux (0.55sec) was arbitrary and was derived from studies evaluating venous insufficiency in the legs |
| | 4. The threshold of reflux (0.55 sec) was arbitrary and was derived from studies evaluating venous insufficiency in the legs |
| (III): High-resolution B-mode evidence of proximal IJV stenosis | 1. The cutoff value of IJV stenosis (cross-sectional area<0.3 cm²) was derived from a study evaluating patients in Intensive Care Unit (never studied in healthy controls) |
| | 2. Physiologic dilatations of IJV (superior & inferior bulb) may lead to false-positive diagnosis of IJV stenosis distal to the dilatation |
| | 3. No definition of location of the designated normal reference |
| | 4. Cervical vein compression by probe or contraction of sternocleidomastoid muscle and intraluminal septation of IJV valve may lead to false-positive diagnosis of IJV stenosis |
| | 5. Cervical venous drainage is dominated by right side and hypoplastic left IJV is a common anatomic variation that may be misdiagnosed as IJV stenosis |
| (IV): Flow not-Doppler detectable in IJV and or VVs | 1. Absent flow in IJV (upright position) or in the Vertebral veins (supine position) does not reflect pathologic condition and has been described in healthy controls |
| | 2. Cervical vein compression by probe or contraction of sternocleidomastoid muscle, incorrect (high) pulse repetition frequency settings may lead to false-positive diagnosis of flow not-Doppler detectable in IJV |
| (V): Reverted postural control of the main cerebral venous outflow in IJVs | 1. Technical challenging (mild compression by probe or muscle contractions may affect IJV diameter leading to false-positive results) |
| | 2. IJV may be completely collapsed in upright position. Deep neck veins and subclavian vein may be misidentified as IJV |
| | 3. Cross-sectional area of IJV may be affected by breathing, neck position, and slight patient movements during insonation leading to low reproducibility of cross-sectional area measurements |

**Evaluation of cerebral venous drainage in MS using other than ultrasound neuroimaging modalities**

In contrast to the CCSVI hypothesis, three Magnetic Resonance Imaging (MRI) studies failed to document a higher prevalence of impaired cerebral or cervical venous flow due to obstructions in cervical or thoracic veins in MS patients in comparison to controls (Sundström et al. 2010; Wattjes et al. 2011; Blinkenberg et al. 2012). Interestingly, a recent MR venography study failed to find increased prevalence of extracranial venous anomalies in children and adolescents with MS in comparison to healthy controls (Jurkiewicz et al. 2014). Moreover, a contrast venography study in 42 MS patients reported that extracranial venous stenosis is an unlikely cause of MS since it is not present in most patients early in the disease and rarely involves more than one extracranial vein (Yamout et al. 2010).

It should also be noted that ultrasound diagnosis of CCSVI was not confirmed when the same patients were evaluated with another neuroimaging modality including
magnetic resonance venography (Blinkenberg et al. 2012; Brod et al. 2013; Costello et al. 2014) or catheter venography (Baracchini et al. 2011; Traboulsee et al. 2014). More specifically, the sensitivity and specificity of the ultrasound criteria for detection of greater than 50% narrowing of any major vein on catheter venography was 40.6% (95% CI: 31.1–50.8%) and 64.3% (48.0–78.0%) in a recent multicenter, double-blinded (blinding of both sonographers and neuro-interventionalists) Canadian study. The highly discrepant results between ultrasound and other neuroimaging modalities lend support to the assumption that CCSVI may constitute a sonographic construct that is unlikely to contribute to MS pathogenesis (Filippi et al. 2011). Finally, Table 3 summarizes the findings of multimodal cross-sectional or case–control neuroimaging studies investigating the CCSVI hypothesis in MS pathogenesis. The majority of these studies failed to validate the CCSVI hypothesis using a combination of different sets of investigations including neurosonology, MR venography, and contrast venography.

**Methodological shortcomings of proposed ultrasound protocol**

The poor reproducibility of CCSVI diagnosis between and within sonographers as well as the low diagnostic yield of ultrasound against other neuroimaging modalities for detection of major cervical vein narrowing may be related to technical reasons including artificial compression of cervical veins by the ultrasound probe or contraction of cervical musculature leading to pseudostenosis, inappropriate selection of pulse repetition frequencies, misinterpretation of pulsation artifact from the adjacent carotid artery as venous reflux, failure to recognize intraluminal jugular septation causing IJV stenosis, misinterpretation of IJV valve insufficiency as IJV stenosis, inadequate patient compliance during sonographic evaluation of cervical veins at different body positions and during different phases of breathing (Baracchini et al. 2011; Tsivgoulis et al. 2011; Valdueza et al. 2013). Another plausible explanation may be associated with the incomplete blinding of the investigators and potential variabilities in the hydration status of MS patients (Comi et al. 2013). In addition, it is also clear that there are enormous variations in normal patterns of cerebral venous drainage within the healthy population, and that interpretation of patterns of venous drainage and venous obstruction can be highly subjective, subject to observer bias, and discrepant from institution to institution, depending upon the particular technology used for assessment as well as the expertise of the sonographers in cerebral and cervical venous ultrasound examinations (Valdueza et al. 2013). The potential methodological shortcomings of the

**Table 5. Critique of published neurosonology images in pivotal studies introducing CCSVI hypothesis (Zamboni 2006; Zamboni et al. 2009a,b,c).**

| Criterion | Methodological Shortcoming |
|-----------|-----------------------------|
| Reflux in cervical veins | Doppler interrogation was not performed simultaneously in Color-Coded images demonstrating venous reflux in cervical veins. Only color-coded images in the transverse section (without complementary color-coded images in horizontal section) were provided. |
| Reflux in deep cerebral veins | Doppler interrogation was not performed simultaneously in Color-Coded images demonstrating venous reflux in cervical veins. Doppler interrogation of deep cerebral veins was not provided. |
| High-resolution B-mode evidence of proximal IJV stenosis | No images of the location of the designated normal reference were provided. There is no comment with regard to the exclusion of left IJV hypoplasia, a common anatomic variation in extracranial veins. |
| Flow not-Doppler detectable in IJV and/or VVs | No images of flow not-Doppler detectable in IJV and/or VVs were provided. Only color-coded images of IJVs in the transverse section were provided. Alternatively, only color-coded images of IJVs in the horizontal section were provided. |
| Reverted postural control of the main cerebral venous outflow | No images of the different patient positions during ultrasound measurements were provided. No images of autoregulation were provided. |
Table 6. Reported complications of “Liberation treatment” for treatment of CCSVI in multiple sclerosis patients.

| Study                        | Description of complication                                                                 |
|------------------------------|---------------------------------------------------------------------------------------------|
| Zamboni et al. (2009c)       | No major complication reported. Mild postprocedural headache with spontaneous resolution (n = 6) |
| Samson (2010)                | Fatal brainstem hemorrhage in a patient treated with coumadin following insertion of two self-regulating stents in the right internal jugular vein (IJV, n = 1). Migration of stent placed in IJV to the right ventricle. Open heart surgery was performed to remove the device (n = 1) |
| Ludyga et al. (2010)         | Stent thrombosis (n = 2). Surgical removal of angiographic balloon (n = 1). Local bleeding from groin (n = 4).
Two cases with femoral artery pseudoaneurysm treated with thrombin injection (n = 2). Gastro-intestinal bleeding requiring hospitalization following clopidogrel treatment after stent placement (n = 1). Transient atrial fibrillation during the procedure requiring pharmacological treatment (n = 2). Migration of stent placed in IJV (n = 4). Second stent placement required to secure the first one (n = 4) |
| Thapar et al. (2011)         | IJV thrombosis following venoplasty (n = 1). Open thrombectomy performed for symptom relief |
| Burton et al. (2011)         | IJV thrombosis following stent placement (n = 1). Cranial nerve palsies (hypoglossal and accessory nerves) caused by bilateral oversized stent placement in IJV (n = 1) |
| Petrov et al. (2011)         | Limited groin hematoma (n = 5), cardiac arrhythmias (n = 6), vein rupture (n = 2), vein dissection (n = 15), acute in-stent/in-segment thrombosis (n = 8), and acute recoil (n = 1) |
| Hubbard et al. (2012)        | Deep vein thrombosis at the venous access site (n = 1) |
| Doležal et al. (2012)        | Dislocation of right IJV stent to ipsilateral brachiocephalic vein and thrombosis of left IJV stent requiring anticoagulation (n = 1) |
| Zamboni et al. (2012)        | Vasovagal syncope reported 3 h after procedure (n = 1) |
| Mandato et al. (2012)        | Neck pain (n = 40), venous thrombosis requiring retreatment within 30 days (n = 3), sustained intraprocedural arrhythmias requiring hospitalization (n = 2), stress-induced cardiomyopathy requiring hospitalization (n = 1) |
| Ghezzi et al. (2013a)        | IJV thrombosis (n = 7), tetraventricular hydrocephalus that needed temporary shunting (n = 1), stroke (n = 1), paroxysmal atrial fibrillation (n = 1), status epilepticus (n = 1), aspiration pneumonia leading to subsequent postoxic encephalopathy (n = 1), hypertension with tachycardia (n = 1), severe bleeding of bed sore due to anticoagulation treatment following the procedure (n = 1) |
| Barbato et al. (2014)        | Bilateral IJV thrombosis leading to occlusion of right IJV and severe stenosis of left IJV in a patient who underwent four procedures of bilateral UV angioplasty and stenting for restenosis |
| Siddiqui et al. (2014)       | Cardiac event (24 h after procedure) treated with pacemaker installation (n = 1) |

proposed neurosonology protocol of CCSVI detection are summarized in Table 4. Finally, Table 5 displays a critical appraisal of available neurosonology images in the pivotal publications by Zamboni and colleagues introducing the CCSVI hypothesis.

Safety and efficacy of “Liberation treatment”

An argument postulated by several groups including patient advocacy groups, media representatives, and physicians is that even with suboptimal accuracy parameters a positive therapeutic effect of venous angioplasty and/or stenting cannot be excluded in MS patients with CCSVI constellations (Pullman et al. 2013; Zivadinov et al. 2013). Consequently, they postulate that access to such interventional therapies should not be refused in the context of randomized-controlled trials, while additional funding and intellectual energy are required to further investigate the venous hypothesis of MS pathogenesis (Zivadinov et al. 2013).

In contrast, there is growing literature underscoring that “Liberation treatment” for CCSVI can be complicated by serious adverse events including IJV or cerebral venous thrombosis, stent dislocation, vein dissection, femoral artery pseudoaneurysm, cranial nerve palsies, syncope or severe cardiac arrhythmias, hydrocephalus, and hemorrhagic complications of anticoagulation initiated following stent placement (Burton et al. 2011; Ghezzi et al. 2013a; Tsvigoulis et al. 2014). Table 6 summarizes the reported complications of “Liberation treatment” across different studies.

Finally, a recently published class I sham-controlled, randomized, double-blind study investigating the safety and efficacy of venous angioplasty in MS patients fulfilling ultrasound criteria of CCSVI showed that venous angioplasty did not improve hemodynamic parameters in...
terms of venous hemodynamic insufficiency severity score as well as clinical outcomes in terms of annualized relapse rate, Expanded Disability Severity Score, and MS Functional Composite (Siddiqui et al. 2014). Moreover, “Liberation treatment” exacerbated underlying disease activity in terms of new T2 and gadolinium-enhancing T1 lesions (Siddiqui et al. 2014). In line with these findings, two recent open-label, retrospective studies also showed an increase in disease activity irrespective of adherence to disease-modifying therapies in patients with MS with CCSVI who underwent venous angioplasty (Alroughani et al. 2013; Ghezzi et al. 2013a).

Conclusions
The postulated hypothesis of a disturbed mechanical cervicospinal venous drain as a monofactorial etiopathogenic mechanism of MS should be discarded in view of the numerous independent external validation studies contradicting Zamboni’s observations and the highly discrepant findings between ultrasound and other neuroimaging modalities. CCSVI appears to be a poorly reproducible and clinically irrelevant sonographic construct. “Liberation treatment” has no proven efficacy, may exacerbate underlying disease activity and has been complicated with serious adverse events. “Liberation treatment” should stop being offered to MS patients even in the settings of randomized-controlled trials, while further unnecessary expenditure of scarce funding resources needs to be discontinued. Physicians taking care of individuals with MS should spend time educating their patients with regard to the scientific evidence refuting CCSVI hypothesis as well as the potential complications and the lack of efficacy of “Liberation” treatment replacing the blogosphere as the main source of “sensational” but inaccurate information.

Acknowledgments
None.

Conflict of Interest
Dr Georgios Tsivgoulis has been supported by European Regional Development Fund - Project FNUSA-ICRC (No. CZ.1.05/1.1.00/02.0123). Dr Tsivgoulis has received research support by Teva Pharmaceutical Hellas and Novartis Hellas. Dr Faisser received travel grants from Biogen Idec. Dr Voumvorakis has received research support by Teva Pharmaceutical Hellas, Merck Hellas, Genesis Pharma and Novartis Hellas. Dr Katsanos reports no disclosures. Dr Triantafyllou reports no disclosures. Dr Grigoriadis has received research support by Teva Pharmaceutical Hellas, Merck Hellas, Genesis Pharma and Novartis Hellas. Dr Gold serves on scientific advisory boards for Teva Pharmaceutical Industries Ltd., Biogen Idec, Bayer Schering Pharma, and Novartis; has received speaker honoraria from Biogen Idec, Teva Pharmaceutical Industries Ltd., Bayer Schering Pharma, and Novartis; serves as editor for Therapeutic Advances in Neurological Diseases and on the editorial boards of American Journal of Pathology and the Journal of Neuroimmunology; and receives research support from Teva Pharmaceutical Industries Ltd., Biogen Idec, Bayer Schering Pharma, Merck Serono, and Novartis. Dr Krogias received travel grants for scientific meetings from Bayer Vital and Bristol-Meyer Squidd.

References
Ackermann, Z., M. Seidenbaum, E. Loewenthal, and A. Rubinow. 1988. Overload of iron in the skin of patients with varicose ulcers. Possible contributing role of iron accumulation in progression of the disease. Arch. Dermatol. 124:1376–1378.
Adams, C. W., R. N. Poston, and S. Buk. 1989. Pathology, histochemistry and immunocytochemistry of lesions in acute multiple sclerosis. J. Neurol. Sci. 92:291–306.
Al-Omari, M. H., and L. A. Rousan. 2010. Internal jugular vein morphology and hemodynamics in patients with multiple sclerosis. Int. Angiol. 29:115–120.
Alroughani, R., S. Lamdhade, and A. Thussu. 2013. Endovascular treatment of chronic cerebrospinal venous insufficiency in multiple sclerosis: a retrospective study. Int. J. Neurosci. 123:324–328.
Baracchini, C., P. Perini, M. Calabrese, F. Causin, F. Rinaldi, P. Gallo. 2011. No evidence of chronic cerebrospinal venous insufficiency at multiple sclerosis onset. Ann. Neurol. 69:90–99.
Barbato, L., F. Scalise, M. A. Grasso, and S. Spagnolo. 2014. Iron man: extreme endovascular treatment for chronic cerebrospinal venous insufficiency. Eur. J. Cardiothorac. Surg. pii:ez294. [Epub ahead of print]
Barkhof, F., and M. P. Wajtje. 2013. Multiple sclerosis: CCSVI deconstructed and discarded. Nat. Rev. Neurol. 9:661–662.
Blinkenberg, M., P. Akeson, H. Sillesen, S. Lövggaard, F. Sellebjerg, O. B. Paulson, H. R. Sibner, et al. 2012. Chronic cerebrospinal venous insufficiency and venous stenoses in multiple sclerosis. Acta Neurol. Scand. 126:421–427.
Brod, S. A., L. A. Kramer, A. M. Cohen, A. D. Barreto, T. T. Bui, J. R. Jemelka, et al. 2013. Chronic cerebrospinal venous insufficiency: masked multimodal imaging assessment. Mult. Scler. 19:1499–1507.
Burton, J. M., K. Alikhani, M. Goyal, F. Costello, C. White, D. Patry, et al. 2011. Complications in MS patients after CCSVI procedures abroad (Calgary, AB). Can. J. Neurol. Sci. 38:741–746.
Chafe, R., K. B. Born, A. S. Slutsky, and A. Laupacis. 2011. The rise of people power. Nature 472:410–411.
Colleridge-Smith, P. D., P. Thomas, J. H. Scurr, and J. A. Dormandy. 1988. Causes of venous ulceration: a new hypothesis. BMJ 296:1726–1727.

Comi, G., M. A. Battaglia, A. Bertolotto, M. Del Sette, A. Ghezzi, G. Malferri, et al. 2013. Observational case-control study of the prevalence of chronic cerebrospinal venous insufficiency in multiple sclerosis: results from the CoSMo study. Mult Scler 19:1508–1517.

Costello, F., J. Modi, D. Lautner, D. Bhayana, J. N. Scott, W. J. Davenport, et al. 2014. Validity of the diagnostic criteria for chronic cerebrospinal venous insufficiency and association with multiple sclerosis. CMAJ 186:E418–E426.

Doepp, F., F. Paul, J. M. Valdueza, K. Schmierer, and S. J. Schreiber. 2010. No cerebrocervical venous congestion in patients with multiple sclerosis. Ann. Neurol. 68:173–183.

Doležal, O., D. Horáková, Z. Glovinová, and J. Szilásiová. 2012. Serious complication of percutaneous angioplasty with stent implantation in so called “chronic cerebrospinal venous insufficiency” in multiple sclerosis patient. Prague. Med. Rep. 113:289–293.

Dolic, K., K. Marr, V. Valnarov, M. G. Dwyer, E. Carl, J. Hagemeier, et al. 2011. Sensitivity and specificity for screening of chronic cerebrospinal venous insufficiency using a multimodal non-invasive imaging approach in patients with multiple sclerosis. Funct. Neurol. 26:205–214.

Dolic, K., K. Marr, V. Valnarov, M. G. Dwyer, E. Carl, Y. Karmon, et al. 2012. Intra- and extraluminal structural and functional venous anomalies in multiple sclerosis, as evidenced by 2 noninvasive imaging techniques. AJNR Am. J. Neuroradiol. 33:16–23.

Filippi, M., M. A. Rocca, F. Barkhof, R. Bakshi, F. Fazeekas, O. Khan, et al. 2011. Multiple sclerosis and chronic cerebrospinal venous insufficiency: the neuroimaging perspective. AJNR Am. J. Neuroradiol. 32:424–427.

Ghezzi, A., P. Annovazzi, M. P. Amato, E. Capello, P. Cavalla, E. Cocco, et al. 2013a. Adverse events after endovascular treatment of chronic cerebro-spinal venous insufficiency (CCSVI) in patients with multiple sclerosis. Mult. Scler. 19:961–963.

Ghezzi, A., P. Annovazzi, E. Cocco, G. Coarelli, A. Lugasresi, M. Rovaris, et al. 2013b. Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases. Neuroradiol. 34:1633–1637.

Gold, R., C. Linnington, and H. Lassmann. 2006. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129:1953–1971.

Hoijnacki, D., P. Zamboni, A. Lopez-Soriano, R. Galleotti, E. Menegatti, B. Weinstock-Guttman, et al. 2010. Use of neck magnetic resonance venography, Doppler sonography and selective venography for diagnosis of chronic cerebrospinal venous insufficiency: a pilot study in multiple sclerosis patients and healthy controls. Int. Angiol. 29:127–139.

Hubbard, D., D. Ponec, J. Gooding, R. Saxon, H. Sauder, and M. Haacke. 2012. Clinical improvement after extracranial venoplasty in multiple sclerosis. J. Vasc. Interv. Radiol. 23:1302–1308.

Jurkiewicz, E., K. Kotulska, K. Nowak, S. Chelstowska, M. Armata, D. Chmielewski, and M. Biliska. 2014. MR venography in children and adolescents with multiple sclerosis does not show increased prevalence of extracranial veins anomalies. Eur. J. Paediatr. Neurol. 18:218–222.

Krogias, C., A. Schröder, H. Wiendl, R. Hohlfeld, and R. Gold. 2010. “Chronic cerebrospinal venous insufficiency” and multiple sclerosis: critical analysis and first observation in an unselected cohort of MS patients. Nervenarzt 81:740–746.

Krogias, C., G. Tsivgoulis, M. Gron, H. P. Hartung, B. Hemmer, W. Oertel, et al. 2013. Review and analysis of international Case-Control Studies on CCSVI and multiple sclerosis. Akt. Neurol. 40:445–451.

Laupacis, A., E. Lillie, A. Dueck, S. Straus, L. Perrier, J. M. Burton, et al. 2011. Association between chronic cerebrospinal venous insufficiency and multiple sclerosis: a meta-analysis. CMAJ 183:E1203–E1212.

Ludiga, T., M. Kazibudzki, M. Simka, M. Hartel, M. Swierad, J. Pieza, et al. 2010. Endovascular treatment for chronic cerebrospinal venous insufficiency: is the procedure safe? Phlebology 25:286–295.

Mandato, K. D., P. F. Hegener, G. P. Siskin, Z. J. Haskal, M. J. Englander, S. Garla, et al. 2012. Safety of endovascular treatment of chronic cerebrospinal venous insufficiency: a report of 240 patients with multiple sclerosis. J. Vasc. Interv. Radiol. 23:55–59.

Mayer, C. A., W. Pfeilschifer, M. W. Lorenz, M. Nedelmann, I. Bechmann, H. Steinmetz, and U. Ziemann, et al. 2011. The perfect crime? CCSVI not leaving a trace in MS. J. Neurol. Neurosurg. Psychiatry 82:436–440.

Menegetti, E., V. Genova, M. Tessari, A. M. Malagoni, I. Bartolomei, M. Zuolo, et al. 2010. The reproducibility of colour Doppler in chronic cerebrospinal venous insufficiency associated with multiple sclerosis. Int. Angiol. 29:121–126.

Nicolaides, A. N., S. Morovic, E. Menegetti, G. Viselner, and P. Zamboni. 2011. Screening for chronic cerebrospinal venous insufficiency (CCSVI) using ultrasound: recommendations for a protocol. Funct. Neurol. 26:229–248.

Petrov, I., L. Grozdinski, G. Kaninski, N. Iliev, M. Iloska, and A. Radev. 2011. Safety profile of endovascular treatment for chronic cerebrospinal venous insufficiency in patients with multiple sclerosis. J. Endovasc. Ther. 18:314–325.

Pullman, D., A. Zarzecznny, and A. Picard. 2013. Media, politics and science policy: MS and evidence from the CCSVI Trenches. BMC Med. Ethics 14:6.

Rodger, I. W., D. Dilar, J. Dwyer, J. Bienenstock, A. Coret, J. Coret-Simon, et al. 2013. Evidence against the involvement of
chronic cerebrospinal venous abnormalities in multiple sclerosis. A case-control study. PLoS ONE 8:e72495.
Samson, K. 2010. Experimental multiple sclerosis vascular shunting procedure halted at Stanford. Ann. Neurol. 67: A13–A15.
Siddiqui, A. H., R. Zivadinov, R. Benedict, Y. Karmon, J. Yu, M. L. Hartney, et al. 2014. Prospective randomized trial for venous angioplasty in MS. Neurology 83:441–9.
Simka, M., T. Ludygka, M. Kazibudzki, P. Latacz, and M. Swierad. 2012. Multiple sclerosis, an unlikely cause of chronic cerebrospinal venous insufficiency: retrospective analysis of catheter venography. JRSM Short Rep. 3:56.
Singh, A. V., and P. Zamboni. 2009. Anomalous venous blood flow and iron deposition in multiple sclerosis. J. Cereb. Blood Flow Metab. 29:1867–1878.
Sundström, P., A. Wähl, K. Ambarki, R. Birgander, A. Eklund, and J. Malm. 2010. Venous and cerebrospinal fluid flow in multiple sclerosis: a case-control study. Ann. Neurol. 68:255–259.
Takase, S., L. Pascarella, L. lerond, J. J. Bergan, and G. W. Schmid-Schönbein. 2004. Venous hypertension, inflammation and valve remodelling. Eur. J. Vasc. Endovasc. Surg. 28:484–493.
Thapar, A., T. R. Lane, V. Pandey, J. Shalhoub, O. Malik, M. Ellis, et al. 2011. Internal jugular thrombosis post venoplasty for chronic cerebrospinal venous insufficiency. Phlebology 26:254–256.
Traboule, A. L., K. B. Knox, L. Machan, Y. Zhao, I. Yee, A. Rauscher, et al. 2014. Prevalence of extracranial venous narrowing on catheter venography in people with multiple sclerosis, their siblings, and unrelated healthy controls: a blinded, case-control study. Lancet 383:138–145.
Tsivgoulis, G., M. Mantatzis, C. Bogiatzi, K. Vadikolias, K. Voumavourakis, P. Prassopoulos, et al. 2011. Extracranial venous hemodynamics in multiple sclerosis: a case-control study. Neurology 77:1241–1245.
Tsivgoulis, G., T. N. Sergentanis, A. Chan, K. Voumavourakis, N. Triantafyllou, N. Tsapoulos, et al. 2014. Chronic cerebrospinal venous insufficiency and multiple sclerosis: a comprehensive meta-analysis of case-control studies. Ther. Adv. Neurol. Disord. 7:114–136.
Valdueza, J. M., F. Doepf, S. J. Schreiber, van Oosten, B. W., K. Schmierer, F. Paul, and M. P. Wattjes. 2013. What went wrong? The flawed concept of cerebrospinal venous insufficiency. J. Cereb. Blood Flow Metab. 33:657–668.
Wattjes, M. P., B. W. van Oosten, W. L. de Graaf, A. Seewann, J. C. Bot, van den Berg R., et al. 2011. No association of abnormal cranial venous drainage with multiple sclerosis: a magnetic resonance venography and flow-quantification study. J. Neurol. Neurosurg. Psychiatry 82:429–435.
Weibach, F. X., A. Chan, K. V. Toyka, and R. Gold. 2004. The cardioprotector dextroxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune encephalomyelitis. Clin. Exp. Immunol. 135:49–55.
Wilkinson, L. S., C. Bunker, J. C. Edwards, J. H. Scurr, and P. D. Smith. 1993. Leukocytes: their role in the etiopathogenesis of skin damage in venous disease. J. Vasc. Surg. 17:669–675.
Yamout, B., A. Herlopian, Z. Issa, R. H. Habib, A. Fawaz, J. Salame, et al. 2010. Extracranial venous stenosis is an unlikely cause of multiple sclerosis. Mult. Scler. 16:1341–1348.
Zamboni, P. 2006. The Big Idea: iron-dependent inflammation in venous disease and proposed parallels in multiple sclerosis. J. R. Soc. Med. 99:589–593.
Zamboni, P., R. Galeotti, E. Benegetti, A. M. Malagoni, G. Tacconi, S. Dall’Ara, I. Bartolomei, et al. 2009a. Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 80:392–399.
Zamboni, P., E. Menegetti, R. Galeotti, A. M. Malagoni, G. Tacconi, S. Dall’Ara, et al. 2009b. The value of cerebral Doppler venous haemodynamics in the assessment of multiple sclerosis. J. Neurol. Sci. 282:25–31.
Zamboni, P., R. Galeotti, B. Weinstock-Guttman, C. Kennedy, F. Salvi, and R. Zivadinov. 2012. Venous angioplasty in patients with multiple sclerosis: results of a pilot study. Eur. J. Vasc. Endovasc. Surg. 43:116–122.
Zaniewski, M., J. Kostecki, W. Kuczmiak, D. Ziaja, G. Opala, M. Swiat, et al. 2013. Neck duplex Doppler ultrasound evaluation for assessing chronic cerebrospinal venous insufficiency in multiple sclerosis patients. Phlebology 28:24–31.
Zivadinov, R., K. Marr, G. Cutter, M. Ramanathan, R. H. Benedict, C. Kennedy, et al. 2011. Prevalence, sensitivity, and specificity of chronic cerebrospinal venous insufficiency in MS. Neurology 77:138–144.
Zivadinov, R., G. Cutter, K. Marr, M. Ramanathan, R. H. Benedict, N. Bergsand, et al. 2012. No association between conventional brain MR imaging and chronic cerebrospinal venous insufficiency in multiple sclerosis. AJNR Am. J. Neuroradiol. 33:1913–1917.
Zivadinov, R., Y. Karmon, K. Dolic, J. Hagemeier, K. Marr, V. Valnarov, et al. 2013. Multimodal noninvasive and invasive imaging of extracranial venous abnormalities indicative of CCSVI: results of the PREMiSe pilot study. BMC Neurol. 13:151.
Zwischenberger, B. A., M. M. Beasley, D. L. Davenport, and E. S. Xenos. 2013. Meta-analysis of the correlation between chronic cerebrospinal venous insufficiency and multiple sclerosis. Vasc. Endovasc. Surg. 47:620–624.